Pampe

Quick links to important sections

Pampe

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pampe

Property Description
Active ingredient Lansoprazole
Form Delayed Release Capsule, Orally Disintegrating Tablet, Powder for Suspension
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Suppression of gastric acid secretion
Origin Synthetic, Substituted Benzimidazole derivative

What Type of Medicine is Pampe (Lansoprazole)?

Pampe is a medication whose active ingredient, Lansoprazole, is classified pharmacologically as a Proton Pump Inhibitor (PPI), a designation widely recognized within clinical practice. This synthetic compound belongs structurally to the family of Substituted Benzimidazoles, establishing its molecular basis for action. The PPI class functions specifically as a potent Gastric Acid-Pump Inhibitor, placing it within the broader group of Antisecretory Compounds. The drug provides sustained efficacy in reducing gastric acidity, which differentiates it from older, less specific acid-reducing treatments.

Composition and Available Forms of Pampe

The medicinal entity Pampe is manufactured as a Single-ingredient product utilizing Lansoprazole as its active component, designed for Oral administration. It is supplied in multiple specialized Dosage Forms, including the Delayed Release Capsule, the Delayed Release Orally Disintegrating Tablet, and the Powder for Suspension. The availability of the Orally Disintegrating Tablet is a key feature, offering an alternative for patients who may have difficulty swallowing traditional capsules. All formulations utilize specialized enteric coatings to protect the acid-labile Prodrug Lansoprazole from premature destruction by the acidic environment of the stomach, ensuring proper absorption and activation.

General Purpose and Core Benefit of Pampe

The core purpose of Lansoprazole is to achieve pronounced and sustained Suppression of Gastric Acid Secretion in the stomach. By acting as a highly effective Antisecretory Compound, the drug significantly reduces the corrosive potential of the gastric contents. This primary action constitutes the foundational benefit, creating a favorable environment for mitigating issues related to excessive acid exposure, such as the discomfort experienced when acid flows back into the esophagus. The sustained effect is a key benefit recognized in long-term therapeutic strategies.

What side effects are possible with Pampe?

Possible Side Effects and Safety Information

The official safety profile for Lansoprazole (Pampe) is structured by regulatory bodies to categorize documented adverse reactions and necessary safety considerations.

Adverse Reaction Scope

Adverse events reported in regulatory documents are grouped by frequency and affected systems:

  • Most Commonly Reported (incidence ge 1%): Diarrhea, Abdominal pain, Nausea, and Constipation.
  • Common (1% to 10%): Includes reactions such as Headache and Flatulence.
  • System-Organ Classes: Effects are documented across the Gastrointestinal, Nervous System, Renal, Musculoskeletal, and Skin systems.

Serious Adverse Reactions and Duration-Related Risks

Regulatory documentation highlights serious adverse reactions that are generally rare but clinically important:

  • Renal and Skin Reactions: These include Acute Tubulointerstitial Nephritis (TIN) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, which have been reported to occur during treatment.
  • Bone Fracture Risk: Observational studies suggest an increased risk of fractures (hip, wrist, spine) is associated with high-dose and long-term use (a year or longer).
  • Nutritional Deficiencies: Prolonged treatment may be associated with the development of Hypomagnesemia (low magnesium) and Cyanocobalamin (Vitamin B12) Deficiency.
  • Gastrointestinal Risk: Increased risk of C. difficile-Associated Diarrhea and the development of Fundic Gland Polyps with long-term use are documented.

Population and Diagnostic Safety Constraints

Safety statements include constraints specific to certain patient groups and diagnostic procedures:

  • Pediatric Use: The medication is not recommended for use in patients under one year of age for symptomatic gastroesophageal reflux disease (GERD).
  • Hepatic Function: Caution is advised, and dose adjustment may be considered by healthcare providers for patients with severe Hepatic Impairment.
  • Diagnostic Interference: Treatment may elevate Chromogranin A (CgA) levels, which can interfere with diagnostic investigations for certain neuroendocrine tumors; this is noted in regulatory information. Additionally, symptomatic improvement does not exclude the possibility of underlying Gastric Malignancy.

Overdose and Emergency Response

Overdose information for Lansoprazole (Pampe) is derived exclusively from regulatory documentation. The clinical presentation of an acute overdose is officially expected to be similar to the established adverse drug reactions listed in the product safety profile. High-dose exposure has been associated with an increase in plasma concentration and may lead to signs affecting the central nervous system, including dizziness, tremors, and convulsions, or severe manifestations like tetany.

In the event of a suspected overdose, regulatory authorities mandate that individuals must get medical help or contact a Poison Control Center right away. Urgent medical attention is required when severe clinical signs, such as arrhythmias or convulsions, are observed.

Management of an overdose involves immediate symptomatic and supportive treatment. The official documentation notes that procedures such as gastric emptying and the administration of activated charcoal may be considered. A key constraint is the lack of a known specific antidote for Lansoprazole. Furthermore, the substance is not significantly eliminated by haemodialysis, meaning treatment focuses entirely on supportive care and observation until the drug is metabolized. Due to reduced drug clearance, caution and regular supervision are required for patients with moderate to severe hepatic impairment, who must not exceed recommended daily dosage limits.

Therapeutic Uses of Pampe

Main Uses and Benefits of Pampe

Pampe is an anticoagulant medication, commonly referred to as a blood thinner. It is primarily used to prevent and treat various conditions related to the formation of harmful blood clots in the circulatory system.

Primary Indications

  • Prevention of Stroke and Systemic Embolism: In individuals with non-valvular atrial fibrillation (a type of irregular heartbeat), Pampe is used to reduce the risk of stroke and the movement of clots to other parts of the body.
  • Treatment of Deep Vein Thrombosis (DVT): Pampe is utilized to treat clots that form in the deep veins, typically in the legs.
  • Treatment of Pulmonary Embolism (PE): The medication is used to manage blood clots that have traveled to the lungs.
  • Prevention of Recurrent DVT and PE: Following an initial event, Pampe helps reduce the likelihood of these conditions occurring again.
  • Prophylaxis After Surgery: It is used to prevent the formation of blood clots in patients who have recently undergone hip or knee replacement surgery.

Therapeutic Benefits

Unlike traditional anticoagulants that require frequent blood monitoring and dietary restrictions, Pampe works by inhibiting specific proteins in the coagulation cascade. This mechanism offers several clinical benefits:

  • Predictable Anticoagulation: The medication provides a consistent effect on blood thinning, which often eliminates the need for routine laboratory monitoring of clotting levels.
  • Reduction in Thromboembolic Events: By preventing the formation and growth of clots, it lowers the risk of serious complications such as lung damage or neurological impairment caused by stroke.
  • Simplified Management: The pharmacological profile of the medication allows for standardized management across different patient populations.

Eligibility and Restrictions for Use

Pampe (Lansoprazole) eligibility is strictly defined by regulatory authorities based on age, concurrent medication, and certain health conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and pediatric patients 1 year to 17 years of age for specific, short-term indications (e.g., symptomatic GERD, erosive esophagitis). Older adults typically require no dose adjustment for age alone.
Populations for whom use is not recommended Infants (under mathbf1 year of age); use is not recommended as efficacy was not demonstrated in clinical trials. Pregnant women and breastfeeding women (use is generally not recommended due to limited human data or unknown excretion into milk).
Populations for whom use is contraindicated Patients with known severe hypersensitivity to any component. Patients receiving the antiretrovirals Atazanavir or Rilpivirine-containing products. Patients with Phenylketonuria (PKU) if using the orally disintegrating tablet (ODT) formulation.

Eligibility-Related Restrictions

  • Liver Function: Individuals with severe hepatic impairment are eligible for use but require caution, and a dose reduction may be recommended in some regions due to decreased drug clearance.
  • Renal Function: Patients with renal impairment generally require no dosage adjustment according to official labels.
  • Malignancy: A symptomatic response to the medicine does not preclude the presence of gastric malignancy, a critical conditional rule for diagnostic follow-up.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Pampe (Lansoprazole)

The regulatory profile for Pampe (Lansoprazole) is strictly defined by pharmacokinetic interactions related to its acid-suppressing function.

Property Description
Medicinal product categories with documented interactions: Antiretrovirals, Antifungals, Anticancer agents, Gastric pH-dependent medicines, Anticoagulants, Theophylline derivatives.
Specific interacting medicines (if explicitly listed): Atazanavir, Rilpivirine, Nelfinavir (all contraindicated), Methotrexate, Tacrolimus, Warfarin, Theophylline, Sucralfate.

Official Interaction Statements:

  • Co-administration is formally contraindicated with the antiretrovirals Atazanavir, Nelfinavir, and Rilpivirine due to the risk of substantial reduction in their systemic concentration.
  • The medicine alters the bioavailability of drugs for which gastric pH is critical for absorption, potentially reducing the exposure of weak bases like Ketoconazole and Iron salts.
  • Lansoprazole may increase the serum concentration of Methotrexate, particularly during high-dose administration, and increase whole blood concentrations of Tacrolimus.
  • Concomitant use with Warfarin may require monitoring for increases in International Normalized Ratio (INR).
  • Absorption is significantly diminished if taken after food, establishing a mandatory pre-meal administration condition.
  • The medicine must be taken at least 30 minutes before Sucralfate to avoid interference with its absorption.
  • Long-term daily use may lead to the malabsorption or deficiency of Cyanocobalamin (Vitamin B12).

Connection to the overall interaction profile: The official regulatory profile is structurally defined by the drug's fundamental action as an acid-suppressing agent, leading directly to a classification of pH-dependent pharmacokinetic interactions as the core interaction risk. This central mechanism is complemented by documented instances of CYP enzyme-mediated exposure modification (e.g., Tacrolimus) and several specific timing and substance restrictions (e.g., Sucralfate, food) that are formally presented in government-approved labeling.

Mechanism of Action

Modulation of Neurotransmitter Receptor Signaling

Pampe exerts its effect primarily within the central nervous system (CNS) through interaction with specific AMPA glutamate receptors. The drug functions as a non-competitive antagonist, meaning it binds to a site distinct from the glutamate binding site. By engaging this key receptor-mediated signaling pathway, Pampe attenuates the effect of high-frequency glutamatergic transmission on postsynaptic neurons.


Regulation of Synaptic Excitability Cascades

The core mechanism involves modifying the initial molecular steps of the excitatory signaling cascade post-synapse. By reducing the ion flux mediated through the AMPA receptor channel, Pampe suppresses the initiation and propagation of abnormally high-frequency electrical signals. This action results in reduced postsynaptic depolarization and a corresponding decrease in action potential generation.


Influence on Central Physiological Responses

The pharmacological consequence of this AMPA receptor antagonism is a concentration-dependent decrease in cellular excitability across responsive neural networks. This molecular effect serves to modulate overall signaling output in neural circuits linked to glutamatergic transmission, influencing the subsequent functional state of the affected circuit.

Dosage and Administration Information

How to Use Pampe (Lansoprazole)

Lansoprazole is administered exclusively through the oral route, utilizing dosage forms such as the Delayed-Release Capsule, Orally Disintegrating Tablet (ODT), and powder for suspension. The primary administration pattern is once daily (q.d.). Standard initial adult doses for most indications, including symptomatic gastroesophageal reflux disease (GERD) and active duodenal ulcers, typically use 15 mg or 30 mg strengths. Doses for conditions like Zollinger-Ellison Syndrome may require titration up to 180 mg/day, with amounts exceeding 120 mg/day administered in divided doses.

Administration Timing and Handling

Official instructions mandate that the medicine be taken before eating—typically prior to the first meal of the day—to ensure optimal absorption. The delayed-release formulations must not be crushed, chewed, or split, as this compromises the enteric coating essential for protecting the active compound from stomach acid. The ODT and powder for suspension forms offer alternatives for patients who cannot swallow the capsules whole. For administration via nasogastric tube or with soft food, the intact pellets from the capsule may be mixed with a small amount of acidic juice or soft food and swallowed immediately. If a dose is missed, it should be taken as soon as possible, but two doses must never be taken simultaneously to compensate.

Dosage Adjustments

No dosage adjustment is required for older adults or patients with renal impairment. However, a reduced daily dose of 15 mg is specifically mandated for use in patients with severe hepatic impairment. Dosing for pediatric patients (1–11 years old) is based on the child's body weight, further standardizing its administration across varied populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pampe (Lansoprazole)

The research landscape for Pampe (Lansoprazole) consists primarily of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses, which contribute to the available information about its use. The evidence below focuses strictly on the research structure, what was studied, and where limitations exist, drawing only from regulatory and peer-reviewed sources.


Evidence for Use in Erosive Esophagitis and Symptomatic GERD

This section summarizes the available research exploring outcomes related to physical discomfort and inflammatory or irritative states in the esophagus. The research examined short-term treatment in large, controlled trials that included adults with both Erosive Esophagitis (EE) and Symptomatic GERD. Researchers measured outcomes such as the rate of endoscopic documented findings and the daily frequency of symptoms. Studies report how symptoms evolved in the observed populations, with trials describing patterns where subjects achieved documented endoscopic findings and reported changes in heartburn symptoms across the short-term observation period.

Evidence for Use in Peptic Ulcer Healing

This heading covers research where ulcers in the stomach and the upper part of the intestine were the focus. Studies explored the use of Pampe where active duodenal and gastric ulcers were the focus. The main outcomes monitored were the endoscopic ulcer documented findings and patient-reported outcomes describing discomfort. Research also examined specific populations, such as chronic users of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), in studies applied to research examining the occurrence of ulcers associated with these medications.

Key Research Gaps and Uncertainties

The types and consistency of evidence vary across studies. For Zollinger-Ellison Syndrome (ZES), evidence is derived from smaller, non-randomized studies. Follow-up durations were limited in many initial trials, meaning long-term effects are not fully established across all uses and patient types. Subgroup findings are uncertain for certain complex patient characteristics. Data for the youngest pediatric age groups (infants under 1 year) remain insufficient.

Key Studies & References H. pylori Eradication Regimens (Lansoprazole/PPI in Combination Therapy) - Clinical Guideline

Frequently Asked Questions (FAQ)

Common questions about Pampe (FAQ)


Q: Is Pampe considered a strong medicine?

A: Official documents classify Pampe as a Proton Pump Inhibitor (PPI), which is defined as a class of medication that provides potent and sustained suppression of acid in the stomach. This pharmacological classification indicates its highly effective mechanism for reducing gastric acid secretion.


Q: How quickly does Pampe start to work for most people?

A: Studies on Pampe show that the process of acid suppression begins fairly quickly, typically within 1 to 2 hours after the first dose. The drug's action is characterized by a sustained reduction in acid secretion, which is a key pharmacokinetic property described in regulatory documents.


Q: Can Pampe be taken with common over-the-counter pain relievers?

A: The official regulatory interaction profile does not list common, non-prescription pain relievers (such as acetaminophen or ibuprofen) as having known, formal contraindications or major interactions with Pampe. Regulatory documents state that patients should inform their healthcare provider of all concomitant medicines.


Q: Do I need to change my diet while taking Pampe?

A: Official guidance describes the medicine's administration as being taken before eating—typically before the first meal of the day—to ensure optimal absorption. While specific foods are not strictly forbidden, regulatory patient information often refers to general lifestyle measures, such as avoiding symptom triggers, as a complementary action.


Q: Is it normal to feel a little tired when first starting Pampe?

A: Official safety documents indicate that feelings of tiredness (fatigue) and drowsiness have been reported, but they are generally classified as known but uncommon side effects. If side effects persist or cause concern, official guidance directs patients to follow up with a healthcare provider.


Q: What happens if I miss a dose of Pampe?

A: Official instructions provide guidance for missed doses, noting that a patient should never take two doses simultaneously to compensate for one that was missed. For complete information on what to do when a dose is missed, patients should consult the detailed prescribing information.


Q: Can Pampe affect my mood?

A: Regulatory safety information lists mood changes, such as depression or related psychological effects, as a known but rare adverse reaction. Other central nervous system effects, including confusion, are also noted as uncommon in official documents.


Q: How long can a person safely stay on Pampe?

A: The required duration of use is strictly defined by the condition being treated, with many indications approved for short-term use (e.g., 4 to 12 weeks). Official warnings note that chronic use extending beyond 12 months has been associated with an increased risk for specific adverse effects, such as bone fracture and Vitamin B12 deficiency.


Q: What should I do if a minor side effect doesn't go away?

A: General regulatory guidance indicates that patients should follow up with a healthcare provider if any side effect, even a minor one, persists, worsens, or causes concern. This ensures the patient receives appropriate follow-up care.


Q: Is Pampe addictive or habit-forming?

A: Pampe (Lansoprazole) is not classified as a controlled substance by regulatory bodies in countries like the US or UK. Official drug classifications do not designate it as being addictive or habit-forming.


Q: Are there specific tests I need before starting Pampe?

A: There are no mandatory, routine blood tests required for all patients before starting Pampe. However, official warnings state that symptomatic improvement does not rule out the presence of a serious underlying condition, such as gastric malignancy. If symptoms do not improve, regulatory information states that further diagnostic evaluation by a healthcare provider may be necessary.


Q: How long does Pampe stay in the body after I stop taking it?

A: While the medicine's time in the bloodstream is relatively short, with a plasma half-life of about 1.5 hours, the clinical effect of acid suppression is prolonged. After stopping multiple doses, the patient's acid secretion gradually returns to normal over approximately two to four days.


Q: Can Pampe cause problems with sleep?

A: Official regulatory documents list insomnia (difficulty sleeping) as a known adverse reaction. This side effect is typically reported as an uncommon or common finding in clinical studies.


Q: Are there any known interactions between Pampe and birth control pills?

A: The official interaction profile states that Pampe can cause clinically relevant interactions with certain oral contraceptives containing ethinyl estradiol and levonorgestrel. This interaction is described in official documents as potentially altering the concentration of hormonal contraceptives, and the full prescribing information contains further details.


Q: Why is it important to tell my doctor about all my current medications before starting Pampe?

A: It is important because Pampe has documented interactions with numerous other types of medication, including antiretrovirals, antifungals, anticoagulants, and certain chemotherapy agents. These interactions can alter the concentration and safety profile of either medication, as defined in official regulatory listings.


Q: Is it safe to drive or operate machinery while taking Pampe?

A: Official information advises caution because side effects such as dizziness, tiredness, or visual disturbances may occur during treatment. If any of these effects are experienced, regulatory guidance describes the need to avoid driving or operating machinery.


Q: What is the evidence level for Pampe's effectiveness?

A: Official regulatory documents indicate that the efficacy for its approved uses (like Erosive Esophagitis) is based on the findings of large-scale, well-controlled studies, primarily Randomized Controlled Trials (RCTs), as described in the clinical studies section of the label.


Q: Can taking Pampe cause weight changes?

A: Official regulatory safety information lists both weight increase and weight decrease as known reported adverse reactions. These effects are typically classified as uncommon or rare in clinical documentation.


Q: Is it okay to stop taking Pampe suddenly?

A: Regulatory documents state that acid secretion inhibition gradually returns to normal over a few days after cessation. Discontinuation of treatment is generally determined by a healthcare provider.


Q: Does Pampe interact with medicines for blood pressure?

A: The official interaction profile does not list a general contraindication or formal major interaction with the broad class of blood pressure medicines. However, patients are directed to inform their healthcare provider of all concomitant medicines, as Pampe's interaction profile is extensive.


Q: Is it true that Pampe is used for things other than its main purpose?

A: Official documents define its purpose only for a limited set of approved conditions, such as healing ulcers and treating symptomatic GERD. Regulatory information only addresses use within these specific approved indications.


Q: How do doctors monitor the effects of Pampe?

A: For patients on long-term treatment, or those taking specific interacting drugs (like Warfarin), monitoring may be necessary for conditions such as low magnesium levels (hypomagnesemia) or changes to the blood-clotting measure known as the International Normalized Ratio (INR).


Q: Does the time of day matter when taking Pampe?

A: Yes, regulatory instructions state the medicine should be taken once daily. It is recommended to take it in the morning and before eating (30 to 60 minutes before the first meal) to ensure proper absorption and full effectiveness.


Q: Are there any specific lifestyle changes recommended while on Pampe?

A: The primary specific instruction is to take the medicine before eating. While not a drug-specific requirement, official patient materials often refer to general lifestyle measures, such as avoiding symptom triggers like fatty or spicy foods, as a complement to the medication.


Q: If Pampe doesn't work for me, what does that usually mean?

A: A lack of symptomatic response does not necessarily mean the medicine has failed. Official warnings state that symptomatic improvement does not exclude the possibility of an underlying, serious condition like gastric malignancy. If symptoms do not improve, regulatory information states that a follow-up with a healthcare provider may be necessary.


Q: Is Pampe a new drug or has it been around for a while?

A: Pampe (Lansoprazole) is not a new medication. The initial approval for the oral capsule formulation was granted by the FDA in 1995, meaning it has been available for clinical use for several decades.


Q: Why do some people need to take Pampe for a longer time than others?

A: Regulatory documents define different treatment durations based on the specific condition being addressed. For example, short-term treatment of ulcers may be 4 to 8 weeks, while the management of chronic conditions like Zollinger-Ellison Syndrome is considered long-term and may require continuous use.


Q: Can I take Pampe if I have a history of liver problems?

A: Patients with severe hepatic impairment are eligible for use but may be subject to a reduced daily dose according to prescribing information in some regions, due to decreased drug clearance. Official documents describe the need for caution for all liver-related concerns.


Q: What are the signs of a possible allergic reaction to Pampe?

A: Regulatory documents describe signs of a serious allergic reaction (hypersensitivity) as including swelling of the face, tongue, or throat; difficulty breathing or swallowing; fever; and a severe rash like hives. If these signs are experienced, official regulatory guidance indicates that emergency medical attention is required.

How should Pampe be stored and disposed of?

How to Store and Dispose of Pampe

Pampe (Lansoprazole) must be stored according to official regulatory requirements to maintain product quality and effectiveness.


Storage Conditions

Requirement Specifics
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the medicine from freezing and away from high heat, moisture, and light.
Container Keep capsules in the bottle cap closed tightly; Orally Disintegrating Tablets (ODT) must be used immediately after opening the blister.
Child Safety Mandatory to store out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine should not be kept. Patients must ask a healthcare professional or pharmacist for instructions on how to dispose of the product. The medicine must not be emptied into drains or wastewater and should be destroyed in accordance with local medical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pampe found in:

A-Z Index: